Trial Profile
Phase 2 Trial of Pemetrexed (Alimta) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2020
Price :
$35
*
At a glance
- Drugs Pemetrexed (Primary) ; Paclitaxel
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms Panthera
- 15 Mar 2018 Status changed from recruiting to discontinued.
- 26 May 2012 Company added in the association field as reported by EudraCT.
- 18 Jan 2011 Planned end date changed from 1 Nov 2011 to 1 Nov 2013 as reported by ClinicalTrials.gov.